The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.

Haematologica 20121101

DNA damage response by single-strand breaks in terminally differentiated muscle cells and the control of muscle integrity.

Cell death and differentiation 20121101

A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.

Haematologica 20121101

Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.

Bioorganic & medicinal chemistry letters 20121015

Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.

Blood 20121011

Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.

European journal of medicinal chemistry 20121001

Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications.

Cancer biology & therapy 20120901

A novel function of p53: a gatekeeper of retinal detachment.

The American journal of pathology 20120901

Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions.

Cancer 20120901

Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.

The Journal of biological chemistry 20120831

MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120815

Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples.

Investigational new drugs 20120801

The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.

The British journal of dermatology 20120801

Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.

Cancer biology & therapy 20120801

The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation.

Nucleic acid therapeutics 20120801

Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.

Cancer research 20120715

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.

Neuro-oncology 20120701

ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.

Nature chemical biology 20120701

The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3.

Cell cycle (Georgetown, Tex.) 20120701

Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.

Veterinary immunology and immunopathology 20120630

Structure-based design of novel inhibitors of the MDM2-p53 interaction.

Journal of medicinal chemistry 20120614

Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor.

Oncogene 20120607

Chk2 mediates RITA-induced apoptosis.

Cell death and differentiation 20120601

Alpha-melanocyte-stimulating hormone suppresses oxidative stress through a p53-mediated signaling pathway in human melanocytes.

Molecular cancer research : MCR 20120601

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.

Bioorganic & medicinal chemistry letters 20120515

Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.

Molecular carcinogenesis 20120501

Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages.

Journal of cellular physiology 20120501

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.

Leukemia 20120501

p53 and MDM2 are involved in the regulation of osteocalcin gene expression.

Experimental cell research 20120501

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.

Cell cycle (Georgetown, Tex.) 20120501

Reversible induction of PARP1 degradation by p53-inducible cis-imidazoline compounds.

Biochemical and biophysical research communications 20120427

The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation.

Human immunology 20120401

Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells.

Cell cycle (Georgetown, Tex.) 20120401

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.

Cell death & disease 20120401

Structural insights into the dual-targeting mechanism of Nutlin-3.

Biochemical and biophysical research communications 20120330

MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells.

Neuroscience letters 20120328

Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.

Oncogene 20120301

Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.

Cancer 20120215

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

Oncogene 20120209

Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.

Investigational new drugs 20120201

p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition.

The Journal of investigative dermatology 20120201

Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.

Biochemical and biophysical research communications 20120120

Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium.

BMC women's health 20120101

Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance.

PloS one 20120101

p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.

PloS one 20120101

Binding of Translationally Controlled Tumour Protein to the N-terminal domain of HDM2 is inhibited by nutlin-3.

PloS one 20120101

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.

Journal of hematology & oncology 20120101

MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.

Stem cells (Dayton, Ohio) 20111201

Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer.

Journal of drug targeting 20111201

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.

Cell death & disease 20111201

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.

Oncogene 20111117

MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.

Bioorganic & medicinal chemistry letters 20111001

Inhibition of MDM2 attenuates neointimal hyperplasia via suppression of vascular proliferation and inflammation.

Cardiovascular research 20110901

Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110901

The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors.

Cell cycle (Georgetown, Tex.) 20110715

MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.

Biochemical pharmacology 20110701

A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells.

Neoplasia (New York, N.Y.) 20110701

Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis.

Cell death & disease 20110701

Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.

Cancer research 20110615

Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.

European journal of cancer (Oxford, England : 1990) 20110601

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.

Molecular cancer therapeutics 20110601

Mechanism-specific signatures for small-molecule p53 activators.

Cell cycle (Georgetown, Tex.) 20110515

Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy.

Chemical biology & drug design 20110501

Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis.

Investigative ophthalmology & visual science 20110501

miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110501

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

Leukemia 20110501

Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.

Cell death & disease 20110501

Synthetic protocol published for promising anticancer compound.

Future medicinal chemistry 20110501

An Mdm2 antagonist, Nutlin-3a, induces p53-dependent and proteasome-mediated poly(ADP-ribose) polymerase1 degradation in mouse fibroblasts.

Biochemical and biophysical research communications 20110415

Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.

Cell death & disease 20110401

Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy.

Nanomedicine (London, England) 20110401

Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.

Journal of medicinal chemistry 20110310

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.

Blood 20110303

Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.

Cancer science 20110301

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.

Oncotarget 20110301

HMGA2 and p14Arf: major roles in cellular senescence of fibroids and therapeutic implications.

Anticancer research 20110301

Suppression of p53 activity through the cooperative action of Ski and histone deacetylase SIRT1.

The Journal of biological chemistry 20110225

Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110215

Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins.

Journal of the American Chemical Society 20110209

Nutlin-3a is a potential therapeutic for ewing sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110201

MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.

Journal of gastroenterology and hepatology 20110201

Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy.

Acta biomaterialia 20110101

Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.

Apoptosis : an international journal on programmed cell death 20110101

p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma.

Oral oncology 20110101

Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation.

Journal of medicinal food 20110101

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation.

BMC cancer 20110101

Pharmacologic activation of p53 by small-molecule MDM2 antagonists.

Current pharmaceutical design 20110101

Recent advances in the therapeutic perspectives of Nutlin-3.

Current pharmaceutical design 20110101

Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.

PloS one 20110101

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.

Molecular cancer 20110101

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.

BMC cancer 20110101

Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel.

PloS one 20110101

Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts.

Molecular cancer 20110101

Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin.

PloS one 20110101

MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.

Cancer letters 20101228

p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Pigment cell & melanoma research 20101201

mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging.

Aging 20101201

Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.

Molecular cancer therapeutics 20101201

DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.

Aging 20101201

Hypoxia downregulates p53 but induces apoptosis and enhances expression of BAD in cultures of human syncytiotrophoblasts.

American journal of physiology. Cell physiology 20101101

Shifting senescence into quiescence by turning up p53.

Cell cycle (Georgetown, Tex.) 20101101

Weak p53 permits senescence during cell cycle arrest.

Cell cycle (Georgetown, Tex.) 20101101

p53: The pivot between cell cycle arrest and senescence.

Cell cycle (Georgetown, Tex.) 20101101

The p53 inducing drug dosage may determine quiescence or senescence.

Aging 20101101

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Oncotarget 20101101

p53-dependent repression of polo-like kinase-1 (PLK1).

Cell cycle (Georgetown, Tex.) 20101015

Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.

Journal of cancer research and clinical oncology 20101001

HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.

The Journal of biological chemistry 20100917

Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.

Cancer biology & therapy 20100915

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.

Cell death and differentiation 20100901

Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20100801

The C terminus of p53 binds the N-terminal domain of MDM2.

Nature structural & molecular biology 20100801

Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

Assay and drug development technologies 20100801

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53.

British journal of cancer 20100713

MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3.

British journal of haematology 20100701

Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers.

Cancer science 20100601

Decision-making by p53 and mTOR.

Aging 20100601

The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.

Aging 20100601

Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.

Apoptosis : an international journal on programmed cell death 20100501

1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.

Molecular cancer therapeutics 20100501

Role of Mdm4 in drug sensitivity of breast cancer cells.

Oncogene 20100422

Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.

European urology 20100401

Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis.

Cell cycle (Georgetown, Tex.) 20100401

Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines.

Anticancer research 20100401

The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20100315

Foxp3 expression in p53-dependent DNA damage responses.

The Journal of biological chemistry 20100312

Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).

Journal of pharmaceutical and biomedical analysis 20100311

Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli.

Cellular signalling 20100301

Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity.

British journal of haematology 20100301

Differential sensitivity of the inner ear sensory cell populations to forced cell cycle re-entry and p53 induction.

Journal of neurochemistry 20100301

DNA damage response to the Mdm2 inhibitor nutlin-3.

Biochemical pharmacology 20100215

The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia.

Leukemia 20100201

Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells.

Cancer letters 20100101

Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.

Leukemia 20100101

Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.

BMC cancer 20100101

Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.

BMC cancer 20100101

High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity.

Oncology reports 20091201

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.

Clinical cancer research : an official journal of the American Association for Cancer Research 20091201

Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.

Journal of medicinal chemistry 20091126

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

Journal of the National Cancer Institute 20091118

Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells.

Investigative ophthalmology & visual science 20091001

Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha.

Carcinogenesis 20091001

Awakening p53 in senescent cells using nutlin-3.

Aging 20091001

Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3.

Aging 20091001

Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.

The Journal of biological chemistry 20090925

Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.

Leukemia 20090901

Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.

Cell cycle (Georgetown, Tex.) 20090901

MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.

British journal of cancer 20090901

Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity.

Molecular cancer therapeutics 20090901

HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.

Cancer research 20090801

Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking.

Bioorganic & medicinal chemistry letters 20090715

Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.

Current cancer drug targets 20090601

The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.

International journal of oncology 20090501

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.

Blood 20090430

Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.

Leukemia 20090401

Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin.

Cancer research 20090401

Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction.

Cancer letters 20090318

Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions.

Molecular cancer therapeutics 20090301

MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090201

Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.

Cancer research 20090115

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

Annual review of pharmacology and toxicology 20090101

Syntaxin 6, a regulator of the protein trafficking machinery and a target of the p53 family, is required for cell adhesion and survival.

The Journal of biological chemistry 20081107

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.

Leukemia 20081101

MDM2 E3 ubiquitin ligase mediates UT-A1 urea transporter ubiquitination and degradation.

American journal of physiology. Renal physiology 20081101

RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53.

Cell cycle (Georgetown, Tex.) 20081101

Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.

Blood 20081001

E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.

Oncogene 20080911

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.

Leukemia 20080901

NMR screening for lead compounds using tryptophan-mutated proteins.

Journal of medicinal chemistry 20080828

Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation.

Cell cycle (Georgetown, Tex.) 20080801

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

Leukemia 20080701

BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death.

Cell cycle (Georgetown, Tex.) 20080701

Hdm2 and nitric oxide radicals contribute to the p53-dependent radioadaptive response.

International journal of radiation oncology, biology, physics 20080601

Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.

Journal of the American Chemical Society 20080521

Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.

Journal of cellular biochemistry 20080515

Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.

Cancer research 20080501

Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells.

Molecular cancer therapeutics 20080501

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.

Blood 20080401

MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.

Leukemia 20080401

Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53.

Molecular cancer therapeutics 20080401

HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.

Oncogene 20080207

Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells.

Journal of leukocyte biology 20080201

Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells.

Blood 20080201

Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.

Ethnicity & disease 20080101

Exploration of liquid and supercritical fluid chromatographic chiral separation and purification of Nutlin-3--a small molecule antagonist of MDM2.

Journal of pharmaceutical and biomedical analysis 20071221

p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21.

Cancer research 20071015

MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20071001

The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.

Neoplasia (New York, N.Y.) 20071001

Respiratory syncytial virus decreases p53 protein to prolong survival of airway epithelial cells.

Journal of immunology (Baltimore, Md. : 1950) 20070901

Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy.

Cell cycle (Georgetown, Tex.) 20070901

Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma.

Cell death and differentiation 20070701

Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells.

The Prostate 20070601

Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070601

Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.

Current drug metabolism 20070501

Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells.

Leukemia 20070401

Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.

Cancer research 20070401

[TP53 and RB tumor suppressor pathways collaborate in retinoblastoma genesis].

Medecine sciences : M/S 20070401

Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation.

The Journal of biological chemistry 20070126

Antiangiogenic activity of the MDM2 antagonist nutlin-3.

Circulation research 20070105

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

Cancer cell 20061201

Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.

Cell cycle (Georgetown, Tex.) 20061201

Hdmx modulates the outcome of p53 activation in human tumor cells.

The Journal of biological chemistry 20061103

Cancer biology: second step to retinal tumours.

Nature 20061102

Inactivation of the p53 pathway in retinoblastoma.

Nature 20061102

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.

Cancer research 20061101

Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors.

Biochemical pharmacology 20061016

Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.

Cancer research 20061001

Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.

Archives of ophthalmology (Chicago, Ill. : 1960) 20060901

MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.

Molecular cancer therapeutics 20060901

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.

Blood 20060801

A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.

Biochemistry 20060801

(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis.

Experimental cell research 20060715

Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.

Journal of medicinal chemistry 20060629

The epithelial cell transforming sequence 2, a guanine nucleotide exchange factor for Rho GTPases, is repressed by p53 via protein methyltransferases and is required for G1-S transition.

Cancer research 20060615

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

Blood 20060515

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

Blood 20060515

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.

Nature chemical biology 20060401

Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.

Cancer research 20060315

WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53.

The Journal of biological chemistry 20051230

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.

Blood 20051115

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.

Blood 20051101

Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy.

Journal of the American Chemical Society 20050928

Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis.

The Journal of biological chemistry 20041217